Pregnant Women's RSV Vaccination Time is Ticking Away

The U.S. Centers for Disease Control and Prevention (CDC) today published a COCA Now email alert confirming that in most of the continental United States, the ABRYSVO™ respiratory syncytial virus (RSV) vaccine should be given to pregnant women from September through January 31, regardless of year-to-year circulation, when infants would be born during increased RSV activity,

As of late January 2024, numerous indicators show RSV infection decreasing in the U.S. 

Jurisdictions that have different RSV seasonality from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, may consider RSV vaccination of pregnant women after January 31.

The CDC and its Advisory Committee on Immunization Practices recommend the RSV vaccination during 32–36 weeks gestation.

The CDC recently reported among women who were pregnant and ≥32 weeks gestation since September 22, 2023, the overall coverage with the RSV vaccine was 14.4% as of January 13, 2024.

Infants born to unvaccinated mothers should receive Beyfortus™ (nirsevimab). This single-dose, long-acting monoclonal antibody provides immediate, passive immunity protection to the infant against RSV-associated lower respiratory tract disease.

As of 2024, Beyfortus availability has increased in the U.S.

COCA Now emails will be sent as soon as possible after the CDC publishes new content, ensuring clinicians are updated.